Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Unattributed VC | Alive

Total Raised


Last Raised

$3.53M | 5 yrs ago

About Eyetronic Therapie

Eyetronic Therapie provides treatment that can restore vision in patients suffering from neuropathies of the optic nerve, such as glaucoma, by means of non-invasive electrical stimulation of the optic nerve.

Eyetronic Therapie Headquarters Location

Friedrich-Engels-Str. 101

Potsdam, 14473,


+49 331 58 56 79 50

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Eyetronic Therapie

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Eyetronic Therapie is included in 2 Expert Collections, including Medical Devices.


Medical Devices

8,490 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,901 items

Eyetronic Therapie Patents

Eyetronic Therapie has filed 7 patents.

patents chart

Application Date

Grant Date


Related Topics




Neurotechnology, Electrotherapy, Neurophysiology, Neuropsychology, Physical psychiatric treatments


Application Date


Grant Date



Related Topics

Neurotechnology, Electrotherapy, Neurophysiology, Neuropsychology, Physical psychiatric treatments



Latest Eyetronic Therapie News

Eyetronic therapy: New milestone reached with 300 patients treated

Sep 21, 2017

Proven optic nerve stimulation can improve field of vision in patients with glaucoma and other optic neuropathies BERLIN, GERMANY--(Marketwired - Sep 21, 2017) - EBS Technologies, developer and provider of the Eyetronic system for the treatment of visual field loss, announces a new milestone: 300 patients have been treated with the Eyetronic therapy since its market introduction two years ago. Currently, six German eye centers offer patients affected by glaucoma or other optic neuropathies this new non-invasive optic nerve stimulation treatment. The Eyetronic therapy enables a completely new therapeutic approach to patients suffering from glaucoma and other conditions affecting the optic nerve. By applying gentle electrical pulses to the optic nerve cells responsible for vision, the therapy achieves a two-fold effect: neuroprotection, which prevents further cell degeneration; and neurorestoration, which reactivates nerve tissue, resulting in restored vision. The method is based on a proven mode-of-action and published clinical data. Eyetronic is the first and only treatment that has demonstrated to not only slow down disease progression, but to also restore vision1 in glaucoma, the leading cause for irreversible blindness in the world, affecting 70 million people globally. Treatment in six German therapy centers The Eyetronic therapy consists of ten sessions of 70 to 90 minutes each, applied on ten consecutive working days. One of the first centers to introduce the innovative treatment is the Ophthalmology Clinic at Wittenbergplatz, Berlin, Germany. "The Eyetronic therapy allows us to offer patients that could not be helped with current methods a new painfree and low-risk treatment", says Prof. Dr. med. Carl Erb, glaucoma expert and medical director of the clinic. "Before starting the therapy, we examine our patients to determine whether there are still intact areas of their visiual field. This is a crucial requirement for a positive therapy outcome." "This is an important milestone for the company and a strong endorsement of our novel therapy as we expand internationally," says Karl Schweitzer, CEO of EBS Technologies. "With Eyetronic, we offer patients and physicians not only a completely new treatment option, but also the prospect of restored vision, considered impossible before in glaucoma." About EBS Technologies EBS Technologies, based in Berlin, Germany, develops software and hardware for medical stimulation therapies. The company holds several patents in the EU, Japan and the USA and received CE mark based on the successful completion of a multicenter randomized controlled clinical trial. The system is approved for the treatment of visual field loss caused by neuropathies of the optic nerve. More information on Eyetronic (formerly: EBS therapy) is available under . 1 Gall C, Schmidt S, Schittkowski MP, Antal A, Ambrus GG, Paulus W, et al. (2016) Alternating Current Stimulation for Vision Restoration after Optic Nerve Damage: A Randomized Clinical Trial. PLoS ONE 11(6): e0156134. Contact Information BSKOM

  • When was Eyetronic Therapie founded?

    Eyetronic Therapie was founded in 2007.

  • Where is Eyetronic Therapie's headquarters?

    Eyetronic Therapie's headquarters is located at Friedrich-Engels-Str. 101, Potsdam.

  • What is Eyetronic Therapie's latest funding round?

    Eyetronic Therapie's latest funding round is Unattributed VC.

  • How much did Eyetronic Therapie raise?

    Eyetronic Therapie raised a total of $12.99M.

  • Who are the investors of Eyetronic Therapie?

    Investors of Eyetronic Therapie include Norgine Ventures, High-Tech Grunderfonds, Earlybird Venture Capital and Brandenburg Kapital.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.